Compare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GSK PHARMA ALKEM LABORATORIES/
GSK PHARMA
 
P/E (TTM) x - 51.1 - View Chart
P/BV x 6.6 10.8 61.8% View Chart
Dividend Yield % 0.7 1.5 44.3%  

Financials

 ALKEM LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GSK PHARMA
Mar-19
ALKEM LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5893,595 44.2%   
Low Rs1,2321,253 98.3%   
Sales per share (Unadj.) Rs417.5184.7 226.1%  
Earnings per share (Unadj.) Rs56.326.3 214.1%  
Cash flow per share (Unadj.) Rs64.729.2 221.9%  
Dividends per share (Unadj.) Rs12.7020.00 63.5%  
Dividend yield (eoy) %0.90.8 109.1%  
Book value per share (Unadj.) Rs292.9126.3 231.9%  
Shares outstanding (eoy) m119.57169.40 70.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.413.1 25.7%   
Avg P/E ratio x25.192.2 27.2%  
P/CF ratio (eoy) x21.883.1 26.2%  
Price / Book Value ratio x4.819.2 25.1%  
Dividend payout %22.676.1 29.7%   
Avg Mkt Cap Rs m168,653410,626 41.1%   
No. of employees `000NA5.0 0.0%   
Total wages/salary Rs m9,1715,372 170.7%   
Avg. sales/employee Rs ThNM6,306.7-  
Avg. wages/employee Rs ThNM1,083.1-  
Avg. net profit/employee Rs ThNM898.0-  
INCOME DATA
Net Sales Rs m49,91531,281 159.6%  
Other income Rs m1,6451,023 160.8%   
Total revenues Rs m51,56132,304 159.6%   
Gross profit Rs m8,4826,009 141.2%  
Depreciation Rs m1,006486 207.0%   
Interest Rs m6716 11,176.7%   
Profit before tax Rs m8,4516,540 129.2%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m1,6062,373 67.7%   
Profit after tax Rs m6,7314,454 151.1%  
Gross profit margin %17.019.2 88.5%  
Effective tax rate %19.036.3 52.4%   
Net profit margin %13.514.2 94.7%  
BALANCE SHEET DATA
Current assets Rs m27,06220,061 134.9%   
Current liabilities Rs m15,32414,543 105.4%   
Net working cap to sales %23.517.6 133.3%  
Current ratio x1.81.4 128.0%  
Inventory Days Days6757 117.1%  
Debtors Days Days4114 293.6%  
Net fixed assets Rs m12,61014,343 87.9%   
Share capital Rs m2391,694 14.1%   
"Free" reserves Rs m34,49019,704 175.0%   
Net worth Rs m35,02721,398 163.7%   
Long term debt Rs m1,2122 60,580.0%   
Total assets Rs m54,38739,113 139.0%  
Interest coverage x13.61,091.0 1.2%   
Debt to equity ratio x00 37,009.4%  
Sales to assets ratio x0.90.8 114.8%   
Return on assets %13.611.4 119.4%  
Return on equity %19.220.8 92.3%  
Return on capital %24.931.9 77.9%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,563534 1,229.1%   
Fx outflow Rs m3,0127,091 42.5%   
Net fx Rs m3,552-6,557 -54.2%   
CASH FLOW
From Operations Rs m7,2593,994 181.7%  
From Investments Rs m1,864-1,433 -130.1%  
From Financial Activity Rs m-9,273-3,584 258.8%  
Net Cashflow Rs m-150-1,023 14.7%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 33.1 10.2 324.5%  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 102,036 67.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

What Should You Do in Today's Volatile Markets?(Podcast)

The week gone by was pretty volatile for Dalal street and the global environment is as unpredictable as it can get.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Small Cap Stocks Could Triple in Less than 2 Years... Here's Why(Profit Hunter)

Sep 30, 2019

Historical data backs up my conviction.

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Sep 30, 2019

Select dividend stocks can be very rewarding.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Oct 11, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - AUROBINDO PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS